Androgen receptor aberrations and abiraterone/enzalutamide-resistant prostate cancer
نویسندگان
چکیده
Disclosures/Conflicts of Interest: GA has received honoraria, consulting fees or travel support from Astellas, Medivation, Janssen, Millennium Pharmaceuticals, Ipsen, Ventana, Bayer, Essa Pharma, Abbott Labs, Novartis, Veridex and Sanofi-Aventis, and grant support from Janssen, AstraZeneca, Innocrin and Arno. The Institute of Cancer Research developed abiraterone and therefore has a commercial interest in this agent. GA is on the ICR list of rewards to inventors for abiraterone. ESA has served as a paid consultant/advisor for Janssen, Astellas, Essa, and Medivation; has received research funding to his institution from Janssen, Johnson & Johnson, Medivation, and Tokai; and is a co-inventor of a biomarker technology that has been licensed to Tokai.
منابع مشابه
Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer
Considerable evidence from both clinical and experimental studies suggests that androgen receptor variants, particularly androgen receptor variant 7 (AR-V7), are critical in the induction of resistance to enzalutamide and abiraterone. In this study, we investigated the role of AR-V7 in the cross-resistance of enzalutamide and abiraterone and examined if inhibition of AR-V7 can improve abiratero...
متن کاملTargeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280-2. ...
متن کاملAndrogen deprivation therapy increases the sensitivity of human prostate carcinoma cells to T cell-mediated lysis through an androgen receptor dependent mechanism
Despite recent advances in diagnosis and therapy, prostate cancer remains the most frequently diagnosed nonskin cancer in the United States and the third leading cause of cancer deaths. Failure of chemotherapies and hormone-deprivation therapies is the major cause of death in patients with castration-resistant prostate cancer (CRPC). Currently, the androgen inhibitors Enzalutamide and Abiratero...
متن کاملAndrogen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
PURPOSE Although novel agents targeting the androgen-androgen receptor (AR) axis have altered the treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC), development of therapeutic resistance is inevitable. In this study, we examined whether AR gene aberrations detectable in circulating cell-free DNA (cfDNA) are associated with resistance to abiraterone acetate and enzalu...
متن کاملPersonalized Medicine and Imaging Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer ArunA.Azad, StanislavV. Volik,AlexanderW.Wyatt,AnneHaegert, StephaneLeBihan,
Purpose: Although novel agents targeting the androgen– androgen receptor (AR) axis have altered the treatment paradigm ofmetastatic castration-resistant prostate cancer (mCRPC), development of therapeutic resistance is inevitable. In this study, we examined whether AR gene aberrations detectable in circulating cell-free DNA (cfDNA) are associated with resistance to abiraterone acetate and enzal...
متن کاملAndrogen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway
Despite recent advances in diagnosis and management, prostrate cancer remains the second most common cause of death from cancer in American men, after lung cancer. Failure of chemotherapies and hormone-deprivation therapies is the major cause of death in patients with castration-resistant prostate cancer (CRPC). Currently, the androgen inhibitors enzalutamide and abiraterone are approved for tr...
متن کامل